| Literature DB >> 24387160 |
Hsi-Yi Yeh, Bing-Hsien Liu, Martin Sieber, Shan-Hui Hsu1.
Abstract
BACKGROUND: Three-dimensional (3D) multicellular spheroids of mesenchymal stem cells (MSCs) are generally regarded to have beneficial properties over MSCs in monolayer. Recent literatures have documented that MSCs can self-assemble into 3D spheroids with a greater capacity for differentiation into various cell types when grown on chitosan (CS), a biopolymer. The genomic modulation occurring in these MSC spheroids is thus of essential importance for understanding their uniqueness and therapeutic potentials. In this study, 3D spheroids self-assembled from human umbilical cord MSCs grown on CS membranes were analyzed by mRNA as well as microRNA microarrays, which helped identify the critical signaling events that may alter the cellular functions during the spheroid forming process.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24387160 PMCID: PMC4046657 DOI: 10.1186/1471-2164-15-10
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Surface properties of cell culture substrates. (A) The static contact angle of CS and TCPS. (B) The surface zeta potential of CS and TCPS. (C) The amount of surface-bound calcium on CS or TCPS after being soaked in the culture medium for 24 h without cells. * P < 0.05 among the indicated groups (n = 3).
Figure 2Phenotype of MSCs grown on CS or TCPS. (A) The morphologies of MSCs on CS or TCPS after 16 h, 24 h and 72 h. (B) The cell viability of MSC spheroids on CS after 24 h analyzed by flow cytometry. The percentage of cells without being stained by PI was defined as the cell viability.
Figure 3The results of microarrays for MSCs grown on CS or TCPS. (A) The screening of the miRNA microarray for MSCs grown on CS or TCPS. (B) The numbers of genes that were subjected to cross-correlation analysis of mRNA and miRNA microarrays and the numbers of screened genes based on the cross-correlation analysis. A complete list of screened genes as well as their expression ratios is shown in Additional file 2.
The group of calcium signaling-associated genes screened from microarrays
| Gene symbol | Gene full name | Ratio (MA) | Ratio (qRT-PCR) |
|---|---|---|---|
| ATP2B1 | ATPase, Ca++ transporting, plasma membrane 1 | 2.40 | 3.17 ± 0.88* |
| ATP2B4 | ATPase, Ca++ transporting, plasma membrane 4 | 0.48 | 0.68 ± 0.23* |
| SLC8A1 | solute carrier family 8 (sodium/calcium exchanger), member 1 | 0.22 | 0.40 ± 0.15* |
| TRPA1 | transient receptor potential cation channel, subfamily A, member 1 | 4.46 | 24.58 ± 16.15* |
| TRPC4 | transient receptor potential cation channel, subfamily C, member 4 | 0.21 | 0.02 ± 0.01* |
| HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | 10.36 | 26.92 ± 10.07* |
| HTR7 | 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled | 2.99 | - |
| PDGFRA | platelet-derived growth factor receptor, alpha polypeptide | 3.29 | 3.38 ± 1.17* |
| GPR68 | G protein-coupled receptor 68 | 4.33 | 10.80 ± 1.42* |
| F2R | coagulation factor II (thrombin) receptor | 2.26 | 6.98 ± 1.53* |
| BDKRB2 | bradykinin receptor B2 | 2.59 | - |
| EDNRA | endothelin receptor type A | 2.27 | - |
| ADRB2 | adrenoceptor beta 2, surface | 0.35 | - |
| MAP3K8 | mitogen-activated protein kinase kinase kinase 8 | 3.61 | 13.31 ± 2.04* |
| ITPR1 | inositol 1,4,5-trisphosphate receptor, type 1 | 2.23 | 2.36 ± 0.32* |
| PLA2G4A | phospholipase A2, group IVA (cytosolic, calcium-dependent) | 5.51 | 6.44 ± 2.70* |
| RASGRP3 | RAS guanyl releasing protein 3 (calcium and DAG-regulated) | 4.35 | 2.78 ± 0.90* |
| CALM2 | calmodulin 2 (phosphorylase kinase, delta) | 0.30 | 0.08 ± 0.05* |
MA: based on microarray data.
qRT-PCR: based on quantitative RT-PCR analysis.
*P < 0.05 between CS and TCPS groups (n = 5).
The group of adhesion and migration/cytoskeleton-associated genes screened from microarrays
| Gene symbol | Gene full name | Ratio (MA) | Ratio (qRT-PCR) |
|---|---|---|---|
| ITGB8 | integrin, beta 8 | 5.48 | 5.28 ± 2.30* |
| ITGA2 | integrin, alpha 2 | 2.73 | - |
| ITGA10 | integrin, alpha 10 | 2.66 | - |
| ITGA11 | integrin, alpha 11 | 2.68 | - |
| ITGB1 | integrin, beta 1 | 0.32 | - |
| ITGA6 | integrin, alpha 6 | 0.33 | - |
| MMP10 | matrix metallopeptidase 10 (stromelysin 2) | 14.14 | 39.10 ± 12.35* |
| MMP1 | matrix metallopeptidase 1 (interstitial collagenase) | 3.71 | 2.75 ± 0.72* |
| MMP3 | matrix metallopeptidase 3 (stromelysin 1, progelatinase) | 2.23 | - |
| CDH18 | cadherin 18, type 2 | 3.14 | 5.46 ± 3.08* |
| PCDH18 | protocadherin 18 | 8.20 | 4.18 ± 1.70* |
| PECAM1 | platelet/endothelial cell adhesion molecule 1 | 3.25 | 2.68 ± 1.04* |
| NOTCH3 | notch 3 | 2.24 | 2.40 ± 0.43* |
| DLL1 | delta-like 1 (Drosophila) | 2.51 | 2.27 ± 0.19* |
| EPHA7 | EPH receptor A7 | 20.49 | 12.34 ± 4.95* |
| SGCG | sarcoglycan, gamma (35 kDa dystrophin-associated glycoprotein) | 2.05 | - |
| SHC4 | SHC (Src homology 2 domain containing) family, member 4 | 2.36 | - |
| PTPRB | protein tyrosine phosphatase, receptor type, B | 2.55 | - |
| SORBS2 | sorbin and SH3 domain containing 2 | 8.31 | 7.11 ± 1.90* |
| DMD | dystrophin | 0.48 | 0.38 ± 0.06* |
| CCBE1 | collagen and calcium binding EGF domains 1 | 0.25 | 0.19 ± 0.07* |
| HMMR | hyaluronan-mediated motility receptor (RHAMM) | 0.23 | 0.29 ± 0.06* |
| CMKLR1 | chemokine-like receptor 1 | 49.04 | 93.69 ± 36.86* |
| CXCR4 | chemokine (C-X-C motif) receptor 4 | 13.40 | 16.61 ± 4.90* |
| CXCR7 | chemokine (C-X-C motif) receptor 7 | 4.60 | 10.78 ± 4.99* |
| CXCL10 | chemokine (C-X-C motif) ligand 10 | 4.10 | 8.99 ± 4.86* |
| CCL2 | chemokine (C-C motif) ligand 2 | 3.44 | - |
| CCL7 | chemokine (C-C motif) ligand 7 | 2.83 | - |
*P < 0.05 between CS and TCPS groups (n = 5).
The group of development-associated genes screened from microarrays
| Gene symbol | Gene full name | Ratio (MA) | Ratio (qRT-PCR) |
|---|---|---|---|
| TGFB3 | transforming growth factor, beta 3 | 2.83 | 2.55 ± 0.89* |
| BMP2 | bone morphogenetic protein 2 | 3.00 | 9.79 ± 3.33* |
| HGF | hepatocyte growth factor (hepapoietin A; scatter factor) | 2.56 | 7.89 ± 2.73* |
| IGF1R | insulin-like growth factor 1 receptor | 2.16 | 2.26 ± 0.71* |
| INSR | insulin receptor | 2.02 | - |
| KDR | kinase insert domain receptor (a type III receptor tyrosine kinase) | 2.19 | 5.30 ± 1.48* |
| KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | 4.50 | 6.21 ± 1.23* |
| EGF | epidermal growth factor | 0.21 | - |
| HBEGF | heparin-binding EGF-like growth factor | 0.35 | - |
| CTGF | connective tissue growth factor | 0.16 | - |
| BDNF | brain-derived neurotrophic factor | 0.13 | 0.33 ± 0.10* |
| GHR | growth hormone receptor | 0.44 | - |
| WLS | wntless homolog | 3.31 | 3.95 ± 0.71* |
| LEF1 | lymphoid enhancer-binding factor 1 | 7.09 | 2.14 ± 0.16* |
| TCF7 | transcription factor 7 (T-cell specific, HMG-box) | 3.79 | 1.35 ± 0.03* |
| DAAM1 | dishevelled associated activator of morphogenesis 1 | 3.17 | 3.61 ± 0.60* |
| WNT2 | wingless-type MMTV integration site family member 2 | 3.83 | 4.66 ± 0.85* |
| LRP4 | low density lipoprotein receptor-related protein 4 | 2.28 | - |
| DGKG | diacylglycerol kinase, gamma 90 kDa | 2.56 | - |
| CXXC4 | CXXC finger protein 4 | 14.52 | 7.21 ± 1.02* |
| RARB | retinoic acid receptor, beta | 4.50 | 1.68 ± 0.16* |
| EGR2 | early growth response 2 | 26.55 | 25.32 ± 4.83* |
* P < 0.05 between CS and TCPS groups (n = 5).
The group of antiinflammatory and antitumor genes screened from microarrays
| Gene symbol | Gene full name | Ratio (MA) | Ratio (qRT-PCR) |
|---|---|---|---|
| IL1A | interleukin 1, alpha | 2.12 | 3.48 ± 1.09* |
| IL1B | interleukin 1, beta | 2.12 | - |
| IL1RN | interleukin 1 receptor antagonist | 6.33 | 5.72 ± 0.88* |
| IL33 | interleukin 33 | 3.85 | - |
| IRAK2 | interleukin-1 receptor-associated kinase 2 | 2.50 | - |
| IL4I1 | interleukin 4 induced gene 1 | 2.34 | - |
| IL24 | interleukin 24 | 4.77 | 18.59 ± 10.05* |
| IL6ST | interleukin 6 signal transducer (gp130, oncostatin M receptor) | 4.07 | - |
| LIF | leukemia inhibitory factor | 2.02 | 3.70 ± 1.77* |
| TNFAIP8L3 | tumor necrosis factor, alpha-induced protein 8-like 3 | 13.87 | 10.28 ± 2.41* |
| TNFAIP8 | tumor necrosis factor, alpha-induced protein 8 | 3.89 | 7.02 ± 1.75* |
| TNFAIP6 | tumor necrosis factor, alpha-induced protein 6 | 3.31 | - |
| TNFSF13B | tumor necrosis factor (ligand) superfamily, member 13b | 2.50 | - |
| TNFSF9 | tumor necrosis factor (ligand) superfamily, member 9 | 2.36 | - |
| TNFRSF11B | tumor necrosis factor receptor superfamily, member 11b | 2.23 | - |
| C1QTNF6 | C1q and tumor necrosis factor related protein 6 | 2.43 | - |
| PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | 4.71 | 15.09 ± 1.73* |
| TP53 | tumor protein p53 | 2.11 | 1.48 ± 0.03* |
*P < 0.05 between CS and TCPS groups (n = 5).
Other significant genes screened from microarrays
| Gene symbol | Gene full name | Ratio (MA) | Ratio (qRT-PCR) |
|---|---|---|---|
| AHR | aryl hydrocarbon receptor | 3.48 | 4.29 ± 1.33* |
| ARNT2 | aryl-hydrocarbon receptor nuclear translocator 2 | 2.12 | - |
| CYP1B1 | cytochrome P450, family 1, subfamily B, polypeptide 1 | 7.66 | 10.91 ± 0.57* |
| CYP19A1 | cytochrome P450, family 19, subfamily A, polypeptide 1 | 5.48 | - |
| CYP3A5 | cytochrome P450, family 3, subfamily A, polypeptide 5 | 3.95 | - |
| FOXO1 | forkhead box O1 | 2.22 | 1.75 ± 0.17* |
| HS3ST1 | heparan sulfate (glucosamine) 3-O-sulfotransferase 1 | 16.47 | 9.06 ± 1.16* |
| G0S2 | G0/G1switch 2 | 7.67 | - |
| CDKN2B | cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) | 3.65 | 6.00 ± 1.73* |
| INHBB | inhibin, beta B | 0.16 | 0.26 ± 0.13* |
* P < 0.05 between CS and TCPS groups (n = 5).